B.r.a.h.m.s Gmbh

Jan Kunde

Stefan Gehrig

Jan Wiemer

Tobias Stubbe

Friedrich Köhler

The invention relates to a method for determining whether a subject diagnosed with a cardiovascular disease should be prescribed a remote patient management, the method comprising measuring particular biomarkers in a sample from said patient. The invention therefore relates to a method for therapy guidance, stratification and/or monitoring of a remote patient management for a patient diagnosed with a cardiovascular disease, comprising providing at least one sample of a patient, determining a level of at least one biomarker selected from the group consisting of proADM, proBNP and proANP or fragment(s) and comparing said level of the at least one biomarker to one or more reference values, wherein said level is indicative of prescribing or not prescribing a remote patient management for said patient. In some embodiments a low benefit level of the at least one biomarker is indicative of not prescribing a remote patient management, whereas in some embodiments a high benefit level of the at least one biomarker is indicative of prescribing a remote patient management. In some embodiments the cardiovascular disease is heart failure, in particular a chronic heart failure that has led to a hospitalization within the last 12 months.

Growing community of inventors

Hennigsdorf, Germany

Jan Kunde